Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03121586 · ClinicalTrials.gov registry record · Phase 3
Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia
A Phase 3 study, sponsored by ACADIA Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 995
- Enrollment target
NCT03121586: Clinical Trial Phase 3 study, sponsored by ACADIA Pharmaceuticals.
NCT03121586 is a Phase 3 study that was terminated before completion, run by ACADIA Pharmaceuticals. The registered enrollment target is 995 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (29% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03121586, a Phase 3 study, was terminated before completion, sponsored by ACADIA Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 995 participants
- Enrollment target
Study Summary
To evaluate the long-term safety and tolerability of pimavanserin after 52 weeks of adjunctive treatment in subjects with schizophrenia
Primary Outcome
Number of patients with treatment emergent adverse events
Interventions
- DRUG Pimavanserin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 995 participants |
| Start Date | 2017-01 |
| Est. Completion | 2024-05-30 |
| Phase | Phase 3 |
Why NCT03121586 stopped before completion
NCT03121586 is an interventional study that assigns participants to a tested intervention. The registered 995 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (29% higher).
The record links to 0 conditions, and to 1 intervention - of which Pimavanserin is the first listed.
NCT03121586 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03121586 about?
NCT03121586 is a clinical study titled "Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia". To evaluate the long-term safety and tolerability of pimavanserin after 52 weeks of adjunctive treatment in subjects with schizophrenia
What is the current status of trial NCT03121586?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 995 participants. The study started on 2017-01. Estimated completion is 2024-05-30.
What interventions are being tested in trial NCT03121586?
The interventions under investigation include: Pimavanserin (DRUG).
Who is sponsoring clinical trial NCT03121586?
This trial is sponsored by ACADIA Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03121586's enrollment target sits among peer trials
995 313th of 2000 higher than 1,688 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07005024 · 996 participants · Phase 3
DOAC - Dosing Options in AntiCoagulation Prophylaxis
- NCT05437575 · 994 participants · Phase 3
Prehospital Analgesia INtervention Trial (PAIN)
- NCT06671704 · 994 participants · NA
GC-PRO Intervention
- NCT05987241 · 992 participants · Phase 2
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia